Aktuellt
SENASTE
Redeye returns with a more in-depth take on the discontinuation of Cranial. We update our financial forecasts on all time horizons, rendering a new fair value range. We are encouraged about the strategy shift and glad to see it initiated earlier than we expected. With an entirely focused orthobiologics business and the SEK150m directed share issue, the equity story is strengthened, and the share should see an upward momentum shortly.
LÄS MER
